Jane Street Group LLC Raises Holdings in CG Oncology, Inc. (NASDAQ:CGON)

Jane Street Group LLC increased its position in CG Oncology, Inc. (NASDAQ:CGON) by 240.5% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 195,951 shares of the company’s stock after purchasing an additional 138,400 shares during the period. Jane Street Group LLC’s holdings in CG Oncology were worth $7,393,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Ally Bridge Group NY LLC lifted its stake in CG Oncology by 50.5% in the third quarter. Ally Bridge Group NY LLC now owns 263,266 shares of the company’s stock valued at $9,933,000 after buying an additional 88,390 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of CG Oncology by 114.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 379,664 shares of the company’s stock valued at $14,325,000 after acquiring an additional 202,262 shares during the period. BNP Paribas Financial Markets boosted its stake in CG Oncology by 876.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 26,660 shares of the company’s stock worth $1,006,000 after purchasing an additional 23,931 shares during the period. Deerfield Management Company L.P. Series C grew its position in CG Oncology by 811.9% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 433,540 shares of the company’s stock worth $13,687,000 after purchasing an additional 386,000 shares during the last quarter. Finally, Ensign Peak Advisors Inc purchased a new position in CG Oncology during the 2nd quarter worth $1,912,000. 26.56% of the stock is owned by institutional investors and hedge funds.

CG Oncology Price Performance

CGON stock opened at $28.76 on Friday. The company’s 50-day moving average price is $35.23 and its 200 day moving average price is $34.90. CG Oncology, Inc. has a 52 week low of $25.77 and a 52 week high of $50.23.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.06. The business had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.30 million. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. On average, research analysts expect that CG Oncology, Inc. will post -1.32 earnings per share for the current fiscal year.

Insider Buying and Selling

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $34.54, for a total transaction of $34,540.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on CGON shares. Roth Mkm assumed coverage on shares of CG Oncology in a research note on Tuesday, August 27th. They set a “buy” rating and a $65.00 target price for the company. Bank of America reiterated a “buy” rating and issued a $65.00 target price on shares of CG Oncology in a research note on Tuesday, October 8th. HC Wainwright restated a “buy” rating and set a $75.00 price target on shares of CG Oncology in a research note on Friday, December 6th. UBS Group began coverage on CG Oncology in a report on Thursday, October 24th. They set a “buy” rating and a $60.00 price target for the company. Finally, Roth Capital raised shares of CG Oncology to a “strong-buy” rating in a research note on Tuesday, August 27th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, CG Oncology currently has a consensus rating of “Buy” and a consensus target price of $63.88.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.